title: [Diagnosis and therapy of weakly-acid/non-acidic gastroesophageal reflux disease].
abstract: The therapy of gastroesophageal reflux disease (GERD) is uncomplicated in most cases. However, 20 % of GERD patients suffer from reflux-associated symptoms under therapy with proton pump inhibitors (PPI). The cause of this resistance to PPI-therapy remains unclear. Today, the most discussed theory is the presence of the non- or weakly acidic reflux. Objective measurements of the weakly/non-acidic reflux are available since the development of intraluminal impedance monitoring in combination with pH-monitoring. The therapy of weakly/non-acidic GERD is not well established, so far. In the course of clinical studies the therapeutic spectrum (i. e. modification of the medical therapy, endoscopic anti-reflux procedures or surgical therapy) has to be tested.
authors.affiliation: II. Medizinische Klinik und Poliklinik, München. alexander.meining@lrz.tum.de
authors.forename: A
authors.initials: A
authors.lastname: Meining
authors.forename: M
authors.initials: M
authors.lastname: Bajbouj
authors.forename: H J
authors.initials: HJ
authors.lastname: Stein
authors.forename: R M
authors.initials: RM
authors.lastname: Schmid
mesh_terms: D001418:Baclofen / Q000627:therapeutic use; D017097:Electric Impedance; D004945:Esophagoscopy; D004947:Esophagus / Q000737:chemistry / Q000502:physiology; D018662:Fundoplication; D018755:GABA Agonists / Q000627:therapeutic use; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008365:Manometry; D054328:Proton Pump Inhibitors
chemical_list: D018755:GABA Agonists; D054328:Proton Pump Inhibitors; D001418:Baclofen